Tempest Therapeutics Enters Agreement With Roche To Advance Evaluation Of Amezalpat Combination Therapy
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics has entered into an agreement with Roche to advance the evaluation of a combination therapy involving amezalpat and atezolizumab. Tempest will lead the pivotal study, while Roche will supply atezolizumab. Tempest retains all rights to amezalpat.
October 10, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche will supply atezolizumab for a pivotal study led by Tempest Therapeutics. This collaboration may enhance Roche's presence in the combination therapy market.
Roche's involvement in supplying atezolizumab for the study could enhance its market presence in combination therapies, potentially benefiting RHHBY's stock.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Tempest Therapeutics has partnered with Roche to advance a combination therapy involving amezalpat. Tempest will lead the study and retains all rights to amezalpat, potentially boosting its market position.
The partnership with Roche to advance a combination therapy and Tempest's retention of all rights to amezalpat suggests a strategic move to strengthen its market position, likely leading to a positive impact on TPST's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90